Sage Therapeutics Inc (FRA:SG7)
€ 10.175 -0.385 (-3.65%) Market Cap: 589.40 Mil Enterprise Value: -65.07 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 49/100

SAGE Therapeutics Inc at SVB Leerink CNS Forum (Virtual) Transcript

Jun 29, 2021 / 08:15PM GMT
Release Date Price: €46.84 (-3.10%)
Marc Harold Goodman
SVB Leerink LLC, Research Division - MD of Neuroscience & Senior Research Analyst

All right. Thanks, everyone, for joining us for our last session of day 1 of the SVB Leerink CNS Forum. We are very thankful and lucky to have Sage Therapeutics' management team here. The topic is addressing key areas of debate regarding all data. And we have Barry Greene, CEO; and Steve Kanes, the CMO. And so the goal here is to kind of do a little bit of a fireside chat, Q&A and hit some of the key issues. And so please if we're not hitting the issues that you want to hit, please send us an email, let me know, and I'll try to get the questions asked.

Questions & Answers

Marc Harold Goodman
SVB Leerink LLC, Research Division - MD of Neuroscience & Senior Research Analyst

So I'll just kick it right off and just jump right into it, guys, and just say, look, number one, a key criticism of the data is that you over the powered the study such that the study with stat-sig, but not clinically meaningful. And what are your thoughts about that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot